Regencell Bioscience Holdings Limited RGC
Annual
Quarterly
No annual revenue total was found in REGENCELL BIOSCIENCE HOLDINGS LIMITED's SEC filings.
Regencell Bioscience Holdings Limited (RGC) files with the SEC under industry code 2833, Medicinal Chemicals & Botanical Products. As of Jun 30, 2026 it held $14.2 million in cash and investments and $295,811 in total debt.
Revenue
—
Net income
$-11.70M
-226.5% vs prior year
Operating cash flow
$-7.70M
-147.2% vs prior year
Free cash flow
$-3.27M
+18.5% vs prior year
EPS
$-2.37
-229.2% vs prior year
Dividend per share
None
Shares outstanding
495.88M
+0.3% vs prior year
Net cash
$13.90M
FY 2026
Operating margin
—
Company profile
- Industry
- Medicinal Chemicals & Botanical Products (SIC 2833)
- Listed as
- RGC (Nasdaq)
- Incorporated in
- Cayman Islands
- Headquarters
- Hong Kong
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1829667
Other Medicinal Chemicals & Botanical Products companies
- Definium Therapeutics, Inc. DFTX
- Curaleaf Holdings, Inc. CURLF
- Trulieve Cannabis Corp. TRLV
- Cronos Group Inc. CRON
- TFA Therapeutics, Inc. RAJAF
- Tilray Brands, Inc. TLRY
- SNDL Inc. SNDL
- Aurora Cannabis Inc ACB
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2026 Jun 30, 2026 |
FY 2025 Jun 30, 2025 |
FY 2024 Jun 30, 2024 |
FY 2023 Jun 30, 2023 |
FY 2021 Jun 30, 2021 |
|---|---|---|---|---|---|
| Operating income | -$11.7M | -$3.8M | -$4.7M | -$6.3M | -$1.4M |
| Net income | -$11.7M | -$3.6M | -$4.3M | -$5.9M | -$1.3M |
| Diluted EPS | -$2.37 | -$0.72 | -$0.87 | -$1.19 | — |
| Operating cash flow | -$7.7M | -$3.1M | -$4.0M | -$5.0M | -$767,311 |
| Free cash flow | — | -$3.3M | -$4.0M | -$5.0M | — |
| Total assets | $14.7M | $5.8M | $8.4M | $12.6M | $340,134 |
| Total liabilities | $1.4M | $895,308 | $219,512 | $632,320 | $4.3M |
| Stockholders' equity | $13.3M | $4.9M | $8.2M | $12.0M | -$4.0M |
| Cash and investments | $14.2M | $4.9M | $8.0M | $11.6M | $59,413 |
| Total debt | $295,811 | $544,415 | $85,741 | $463,669 | — |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 20-F | Annual report (foreign issuer) | Oct 7, 2026 | Jun 30, 2026 |
| 6-K | Current report (foreign issuer) | May 22, 2026 | May 22, 2026 |
| 6-K | Current report (foreign issuer) | May 19, 2026 | May 19, 2026 |
| 6-K | Current report (foreign issuer) | May 19, 2026 | May 19, 2026 |
| 6-K | Current report (foreign issuer) | May 8, 2026 | Dec 31, 2025 |
| 6-K | Current report (foreign issuer) | Apr 17, 2026 | Apr 17, 2026 |
All 85 Regencell Bioscience Holdings Limited SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.